http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
-
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
-
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
-
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
-
Phathom Pharmaceuticals Inc. (PHAT) Reports Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
-
Phathom Pharmaceuticals (PHAT) Reports Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
-
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
-
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
-
Phathom Pharmaceuticals Inc. (PHAT) Announces Results VONO-103 Phase 1 Trial
-
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
-
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
-
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
-
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
-
Phathom Pharmaceuticals (PHAT) Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
-
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
-
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
-
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
-
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
-
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
-
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
-
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
-
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
-
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
-
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
-
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
-
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
-
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
-
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
-
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
-
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
-
Phathom Pharmaceuticals (PHAT) Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection Met All Primary and Secondary Endpoints
-
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
-
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
-
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
-
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
-
Phathom Pharmaceuticals Inc. (PHAT) Reports Complete Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
-
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
-
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
-
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
-
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
-
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
-
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
-
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
-
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
-
Arcutis Announces Appointment of Terrie Curran to Board of Directors

